20 research outputs found
A multi‐ethnic analysis of immune‐related gene expression signatures in patients with ovarian clear cell carcinoma
10.1002/path.5769The Journal of Patholog
Update on immune checkpoint inhibitors in gynecological cancers
10.3802/jgo.2017.28.e20JOURNAL OF GYNECOLOGIC ONCOLOGY28
PARP Inhibitors in Breast and Ovarian Cancer
Poly (ADP-ribose) polymerase (PARP) inhibitors are one of the most successful examples of clinical translation of targeted therapies in medical oncology, and this has been demonstrated by their effective management of BRCA1/BRCA2 mutant cancers, most notably in breast and ovarian cancers. PARP inhibitors target DNA repair pathways that BRCA1/2-mutant tumours are dependent upon. Inhibition of the key components of these pathways leads to DNA damage triggering subsequent critical levels of genomic instability, mitotic catastrophe and cell death. This ultimately results in a synthetic lethal relationship between BRCA1/2 and PARP, which underpins the effectiveness of PARP inhibitors. Despite the early and dramatic response seen with PARP inhibitors, patients receiving them often develop treatment resistance. To date, data from both clinical and preclinical studies have highlighted multiple resistance mechanisms to PARP inhibitors, and only by understanding these mechanisms are we able to overcome the challenges. The focus of this review is to summarise the underlying mechanisms underpinning treatment resistance to PARP inhibitors and to aid both clinicians and scientists to develop better clinically applicable assays to better select patients who would derive the greatest benefit as well as develop new novel/combination treatment strategies to overcome these mechanisms of resistance. With a better understanding of PARP inhibitor resistance mechanisms, we would not only be able to identify a subset of patients who are unlikely to benefit from therapy but also to sequence our treatment paradigm to avoid and overcome these resistance mechanisms
Clinical outcome and prognostic factors for Asian patients treated in a phase I study at the National University Cancer Institute, Singapore (NCIS).
A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)
10.1136/ijgc-2020-001604INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER3081239-124
A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies
10.1007/s11523-023-00962-wTARGETED ONCOLOGYcomplete
Dose finding study of varlitinib ± trastuzumab with carboplatin/paclitaxel in advanced solid tumors.
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
10.1158/2159-8290.CD-20-0868CANCER DISCOVERY11180-91complete